HCA Healthcare (NYSE:HCA) Price Target Increased to $390.00 by Analysts at Truist Financial

HCA Healthcare (NYSE:HCA) had its price objective increased by Truist Financial from $375.00 to $390.00 in a research report report published on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts have also recently weighed in on HCA. Oppenheimer increased their target price on HCA Healthcare from $330.00 to $345.00 and gave the company an outperform rating in a report on Monday, April 29th. Cantor Fitzgerald restated an overweight rating and set a $335.00 target price on shares of HCA Healthcare in a report on Tuesday, July 9th. Wells Fargo & Company upped their price target on HCA Healthcare from $303.00 to $315.00 and gave the company an equal weight rating in a research report on Thursday, March 28th. Robert W. Baird initiated coverage on HCA Healthcare in a research report on Thursday, May 30th. They set an outperform rating and a $396.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft upped their price target on HCA Healthcare from $359.00 to $375.00 and gave the company a buy rating in a research report on Friday, June 28th. Four research analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, HCA Healthcare currently has a consensus rating of Moderate Buy and a consensus price target of $339.72.

HCA Healthcare Price Performance

HCA opened at $354.78 on Wednesday. The stock has a 50-day moving average price of $330.12 and a 200-day moving average price of $323.11. HCA Healthcare has a 12-month low of $215.96 and a 12-month high of $356.30. The company has a current ratio of 1.06, a quick ratio of 1.02 and a debt-to-equity ratio of 27.11. The stock has a market capitalization of $92.92 billion, a P/E ratio of 17.69, a PEG ratio of 1.35 and a beta of 1.68.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Tuesday, July 23rd. The company reported $5.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.97 by $0.53. HCA Healthcare had a return on equity of 553.13% and a net margin of 8.40%. The firm had revenue of $17.49 billion during the quarter, compared to analysts’ expectations of $17.05 billion. During the same period in the prior year, the business earned $4.29 EPS. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities analysts predict that HCA Healthcare will post 22.44 earnings per share for the current fiscal year.

HCA Healthcare Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 16th will be given a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend is Monday, September 16th. HCA Healthcare’s dividend payout ratio (DPR) is presently 13.16%.

Insider Buying and Selling at HCA Healthcare

In other HCA Healthcare news, SVP Kathryn A. Torres sold 973 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $312.00, for a total transaction of $303,576.00. Following the sale, the senior vice president now directly owns 22,365 shares in the company, valued at approximately $6,977,880. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other HCA Healthcare news, SVP Kathryn A. Torres sold 973 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $312.00, for a total transaction of $303,576.00. Following the sale, the senior vice president now directly owns 22,365 shares in the company, valued at approximately $6,977,880. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael S. Cuffe sold 1,600 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $309.00, for a total value of $494,400.00. Following the completion of the transaction, the executive vice president now owns 34,124 shares in the company, valued at $10,544,316. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,397 shares of company stock worth $3,921,929. Insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On HCA Healthcare

Institutional investors and hedge funds have recently modified their holdings of the company. MFA Wealth Advisors LLC purchased a new position in HCA Healthcare during the second quarter valued at $27,000. Unique Wealth Strategies LLC purchased a new position in HCA Healthcare during the second quarter valued at $28,000. Bangor Savings Bank lifted its position in HCA Healthcare by 112.5% during the second quarter. Bangor Savings Bank now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 45 shares in the last quarter. GPS Wealth Strategies Group LLC lifted its position in HCA Healthcare by 284.0% during the second quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock valued at $31,000 after purchasing an additional 71 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC bought a new stake in HCA Healthcare during the fourth quarter valued at about $27,000. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.